OP0169 Sarilumab for the treatment of ankylosing spondylitis: Results of a phase 2, randomized. Double-blind, placebo-controlled, international study (align)
Background Sarilumab is the first fully human monoclonal antibody directed against IL-6Rα. Objectives This study evaluated the efficacy and safety of sarilumab in patients with ankylosing spondylitis (AS). Methods Adult patients with active AS for ≥3 months, that were NSAIDs-IR or intolerant, were r...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.111-112 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!